Batoclimab (FCGRT) – Research Grade Biosimilar

Background:

Batoclimab (HBM9161) is fully human antibody targeting neonatal Fc receptor (FcRn). It can accelerate the degradation of autoantibodies in patients with optic neuromyelitis spectrum diseases and other autoimmune diseases. FcRn expression is upregulated by pro-inflammatory cytokines (such as TNF-α) and prolongs the half-life of IgG and serum albumin by reducing lysosomal degradation in endothelial cells and bone marrow-derived cells. Blocking the FcRn-IgG interaction can accelerate the degradation of autoantibodies and mitigate the onset of various pathogenic IgG-mediated autoimmune diseases, including myasthenia gravis, thyroid eye disease, optic neuromyelitis spectrum disease, and immunity Thrombocytopenia.